IDEXX Laboratories, Inc. $IDXX Shares Sold by Townsquare Capital LLC

Townsquare Capital LLC decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 76.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 514 shares of the company’s stock after selling 1,644 shares during the quarter. Townsquare Capital LLC’s holdings in IDEXX Laboratories were worth $328,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the stock. WealthCollab LLC purchased a new position in IDEXX Laboratories during the 2nd quarter valued at about $30,000. J.Safra Asset Management Corp purchased a new stake in IDEXX Laboratories during the 3rd quarter worth about $31,000. Armstrong Advisory Group Inc. boosted its holdings in IDEXX Laboratories by 55.9% in the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after purchasing an additional 19 shares in the last quarter. Salomon & Ludwin LLC acquired a new position in shares of IDEXX Laboratories in the 3rd quarter valued at $35,000. Finally, Ameritas Advisory Services LLC acquired a new stake in shares of IDEXX Laboratories during the second quarter worth about $36,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the business’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the transaction, the executive vice president owned 21,149 shares in the company, valued at $14,874,937.66. The trade was a 30.83% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Trading Down 0.9%

NASDAQ IDXX opened at $670.46 on Friday. The company’s 50 day moving average price is $705.35 and its 200 day moving average price is $660.81. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.87 and a current ratio of 1.18. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98. The firm has a market capitalization of $53.54 billion, a price-to-earnings ratio of 53.17, a PEG ratio of 3.61 and a beta of 1.67.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, November 3rd. The company reported $3.22 EPS for the quarter, beating the consensus estimate of $3.14 by $0.08. The company had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The firm’s revenue was up 13.3% compared to the same quarter last year. During the same period last year, the company posted $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Wall Street Analysts Forecast Growth

IDXX has been the subject of several research reports. Stifel Nicolaus set a $775.00 price target on shares of IDEXX Laboratories in a research report on Monday, November 3rd. JPMorgan Chase & Co. upped their price objective on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Morgan Stanley increased their target price on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Leerink Partners set a $785.00 price objective on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Finally, Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 17th. Seven analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $763.50.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.